Postmenopausal estrogen replacement: a long-term cohort study

Area of Science:

• Endocrinology
• Gerontology
• Cardiovascular Medicine

Background:

• Postmenopausal hormone therapy is a complex treatment with evolving understanding of long-term effects.
• Estrogen replacement therapy (ERT) has been used to manage menopausal symptoms and prevent associated health issues.
• Longitudinal data on the comprehensive health impacts of ERT, including bone health, cardiovascular markers, and physical stature, are crucial.

Purpose of the Study:

• To evaluate the long-term effects of estrogen replacement therapy (ERT) on bone density, height, fracture risk, and cardiovascular biomarkers in postmenopausal women.
• To compare the outcomes of ERT with a control group over an extended period.

Main Methods:

• A prospective, nonrandomized cohort study involving 157 postmenopausal women from 1964 to 1989.
• ERT regimen: 0.625 mg conjugated equine estrogen daily (days 1-25/month) from 1964-1984. From 1984-1989, medroxyprogesterone (5 mg) was added (days 14-25/6th month) for women with intact uterus.
• Measurements included height, cortical bone density (distal radius), fracture incidence, serum lipids (LDL, HDL), and cardiovascular events.

Main Results:

• ERT subjects exhibited significantly less height loss after age 65 (0.08 cm/year vs. accelerated loss in controls).
• Mean cortical bone density was 12.0% higher in ERT subjects; vertebral and peripheral fracture risk was significantly reduced (RR 0.28).
• ERT led to a 21% decrease in LDL and a 37% increase in HDL cholesterol; both ERT and total cholesterol independently affected cardiovascular disease risk.

Conclusions:

• Long-term ERT is associated with preserved height, increased bone density, and reduced fracture risk in postmenopausal women.
• ERT positively impacts lipid profiles, suggesting a potential role in cardiovascular disease prevention.
• These findings underscore the multifaceted benefits of ERT for postmenopausal health over extended periods.